Restart Life Stock Price, News & Analysis

Restart Life Sciences (OTC Pink: NMLSF) signed a binding LOI dated December 21, 2025 to acquire 100% of Holy Crap Foods from Happy Belly Food Group for a CAD$1,000,000 purchase price subject to working capital adjustments.

Restart paid a CAD$100,000 deposit (10% of the price). The transaction includes the Holy Crap brand portfolio and a British Columbia co-packer facility to produce Restart's Brain Balls and other lines. The parties expect closing in early 2026, subject to Canadian Securities Exchange approval, with a business acquisition report due within 75 days of closing. Post-closing payment adjustments may be made within 12 months and will be secured against Holy Crap assets.

Restart Life Sciences (OTC: NMLSF) closed an over-subscribed second tranche of a non-brokered private placement on December 18, 2025, raising gross proceeds of CDN$630,000 in the tranche and CDN$1,130,000 in total across two tranches.

The company issued 6,300,000 units at CDN$0.10 per unit; each unit includes one common share and one transferable warrant exercisable for one year at CDN$0.10. The company also issued 132,000 non-transferable finder warrants exercisable for one year at CDN$0.10. Proceeds are earmarked for health food trials, potential acquisitions, and general working capital. Securities are subject to a four-month-and-one-day hold expiring April 18, 2026.

Restart Life Sciences (OTC Pink: NMLSF) announced on December 17, 2025 that it will allocate capital to support newly planned food-related research initiatives aimed at its consumer health portfolio.

The company said it will narrow preferred research partners, pursue studies on ingredient quality, formulation performance, stability, sensory attributes and preliminary bioavailability, and expects findings to inform product refinement for brands such as BrainQ and BrainBalls. Additional updates will follow as research parameters and partnerships are defined.

Restart Life Sciences (OTC Pink: NMLSF) closed the first tranche of a non-brokered private placement on December 5, 2025, raising CDN$500,000 by issuing 5,000,000 units at CDN$0.10 per unit. Each unit includes one common share and one one-year warrant exercisable at CAD$0.10. The company paid CAD$16,800 in cash finder's fees and issued 60,000 non-transferable finder warrants exercisable at CAD$0.10 for one year. Proceeds are intended for health food trials, potential acquisitions, and general working capital. All securities are subject to a hold period ending April 6, 2026.

Restart Life Sciences Corp. (OTC: NMLSF) has announced the launch of BrainQ, a new wholly-owned brand focused on cognitive health and wellness products. The brand's first product, BrainQ Healthy Cereal, will be produced in partnership with a British Columbia-based co-packing facility and will be available in three flavors, offered in sachets and travel-sized packs. The cereal follows the product line established by BrainBalls and aims to enhance cognitive health and mental clarity. CEO Steve Loutskou recently completed a facility tour to finalize production arrangements, packaging, and logistics. While product formulations and regulatory preparations are in advanced stages, the exact production timeline will align with broader organizational objectives. The company is also developing additional products under the BrainQ brand to expand its wellness-focused portfolio.

Restart Life Sciences Corp. (OTC: NMLSF) has announced the upcoming launch of BrainBalls, a functional wellness snack developed through a joint venture with Brain Balls Inc. The product line features clean-label, plant-based ingredients designed to support mental clarity, cognitive performance, and sustained energy. Initially launching in three flavors - Chocolate, Vanilla, and Blueberry - BrainBalls will be available in family size sachets and multi-pack travel options. The company has overseen all aspects of product development, including formulation, nutritional development, branding, and packaging design. Restart Life is working with third-party manufacturers and logistics partners to ensure quality and scalability, with plans to expand the product line in response to growing consumer demand in the functional food market.

Nova Mentis Life Science Corp. (NMLSF) has entered into an intellectual property conveyance agreement with Ludwig Enterprises Inc. and Dr. Marvin S. Hausman. NOVA will assign its mRNA Neuro Panel and Serotonin Assay intellectual property to Ludwig. In exchange, Hausman will forgive NOVA's $245,712 debt, and Ludwig will issue 750,000 restricted common shares to NOVA. Additionally, NOVA will receive a 10-year royalty of 2.5% on revenue up to $245,712 and 5% thereafter from the Property's commercialization.

NOVA's Health Canada Phase 2a clinical trial for Fragile X Syndrome has faced recruitment challenges, with no candidates meeting enrollment requirements. The company's Board is actively seeking new business opportunities in the Life Sciences sector to create shareholder value.